Get the Stockscreener App
3.18
7.29%
-0.25
After Hours:
3.26
0.08
+2.52%
Cabaletta Bio Inc stock is traded at $3.18, with a volume of 1.62M.
It is down -7.29% in the last 24 hours and up +36.48% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$3.43
Open:
$3.38
24h Volume:
1.62M
Relative Volume:
0.55
Market Cap:
$306.12M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-1.9157
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
-8.62%
1M Performance:
+36.48%
6M Performance:
+87.06%
1Y Performance:
+71.89%
1-Day Range:
$3.155
$3.4238
1-Week Range:
$3.13
$3.44
52-Week Range:
$0.9857
$3.78
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.18 | 330.19M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
CABA SEC FilingsCabaletta Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Are healthcare stocks underperforming Biodesix (BDSX) so far this year? - Bitget
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
Cabaletta Bio (CABA) grants 225,000 stock options to its president - Stock Titan
Cabaletta Bio (CABA) CEO awarded 674,000-share stock option grant - Stock Titan
TD Cowen Health Care Conference - marketscreener.com
Gains Report: Can Cabaletta Bio Inc deliver consistent dividendsJuly 2025 Analyst Calls & Fast Gain Swing Alerts - baoquankhu1.vn
CABA Should I Buy - Intellectia AI
CABA Technical Analysis & ETF Price Forecast - Intellectia AI
Here’s why Jacob Funds established a position in Cabaletta Bio (CABA) - MSN
Millennium Management LLC's Strategic Acquisition of Cabaletta B - GuruFocus
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Short Covering: Will Cabaletta Bio Inc announce a stock split2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
Aug EndMonth: What drives SATLWs stock price2025 Market Sentiment & Stock Market Timing Techniques - baoquankhu1.vn
Dividend Watch: Is PECO stock a falling knife or bargain buyRisk Management & Growth Oriented Trade Recommendations - baoquankhu1.vn
CABA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Market Rankings: Is Cabaletta Bio Inc stock trending bullishJuly 2025 Analyst Calls & High Accuracy Swing Trade Signals - baoquankhu1.vn
Millennium Group (CABA) jointly reports 5.3% holding of 5.13M shares - Stock Titan
Aug Shorts: Does Cabaletta Bio Inc have strong EBITDA marginsJuly 2025 Update & Accurate Buy Signal Notifications - baoquankhu1.vn
Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA) - Insider Monkey
Cormorant discloses Cabaletta Bio (CABA) 9.28% passive ownership stake - Stock Titan
What are Cabaletta Bio Inc.’s recent SEC filings showingPortfolio Update Summary & Daily Risk Controlled Trade Plans - mfd.ru
CABA News & Events - Intellectia AI
Best Swing Trade Stocks Right Now • Updated Daily - Benzinga
Pharma News: Why retail investors favor Cabaletta Bio Inc. stock2025 Historical Comparison & Fast Entry High Yield Tips - mfd.ru
Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA - MarketBeat
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Aug Drivers: Is Cabaletta Bio Inc stock a smart retirement pickJuly 2025 Recap & Fast Moving Market Watchlists - baoquankhu1.vn
CABA News Today | Why did Cabaletta Bio stock go up today? - MarketBeat
Cabaletta Bio Takes Spotlight at Guggenheim Summit as Autoimmune Bet Advances - MyChesCo
Cabaletta Bio shares climb after insider purchases - MSN
Update Recap: Is Cabaletta Bio Inc stock overvalued or fairly priced2025 Macro Impact & AI Powered Market Entry Strategies - baoquankhu1.vn
Trend Review: Is Cabaletta Bio Inc stock overvalued or fairly pricedJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Globe and Mail
Cabaletta Bio to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Risk Off: What is Cabaletta Bio Incs P E ratio telling usJuly 2025 PostEarnings & Weekly High Return Stock Forecasts - baoquankhu1.vn
Swing Trade: Can Cabaletta Bio Inc deliver consistent dividendsQuarterly Earnings Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
US Market Wrap: Can Cabaletta Bio Inc disrupt its industryJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Highs Report: Will Tucows Inc outperform its industry peersMarket Activity Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
What makes Cabaletta Bio, Inc. (CABA) a strong momentum stock: Buy now? - MSN
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Guggenheim reiterates Buy rating on Cabaletta Bio stock, citing commercial plan - Investing.com Nigeria
Cabaletta Bio: Do You Buy With The Insiders? (NASDAQ:CABA) - Seeking Alpha
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Largest borrow rate increases among liquid names - TipRanks
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cabaletta Bio Inc Stock (CABA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | President, Science & Tech. |
Jan 21 '26 |
Buy |
2.19 |
11,312 |
24,763 |
31,312 |
| Tomasello Shawn | Director |
Jan 21 '26 |
Buy |
2.21 |
22,725 |
50,322 |
22,725 |
| Gavel Steve | Chief Commercial Officer |
Jan 21 '26 |
Buy |
2.27 |
22,170 |
50,215 |
22,170 |
| Bollard Catherine | Director |
Jan 21 '26 |
Buy |
2.27 |
4,405 |
9,982 |
5,405 |
| Nichtberger Steven | President & CEO |
Jan 21 '26 |
Buy |
2.24 |
45,000 |
100,778 |
1,031,483 |
| Simon Mark | Director |
Jan 21 '26 |
Buy |
2.28 |
11,061 |
25,261 |
147,205 |
| Gerard Michael | General Counsel |
Jan 21 '26 |
Buy |
2.27 |
6,600 |
14,979 |
6,600 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):